Malaria infection caused by Plasmodium parasites continues to cause enormous morbidity and mortality in areas where it is endemic, and there is no licensed vaccine capable of inducing sterile protection. Hyperimmunization with attenuated whole sporozoites can induce sterile protective immune responses targeting preerythrocytic antigens. Most animal models of hyperimmunization rely on sporozoites dissected from mosquito salivary glands and injected without further purification. In BALB/c mice, repeated small doses of P. yoelii sporozoites progressively expand the population of sporozoite-specific CD8 ؉ T cells. In this study, large secondary doses of unpurified sporozoites unexpectedly led to contraction of sporozoite-specific CD8 ؉ T cell responses in sporozoite-primed mice. While sporozoite-primed CD8 ؉ T cells alternatively can be expanded by secondary exposure to Listeria monocytogenes expressing recombinant Plasmodium antigens, such expansion was potently inhibited by coinjection of large doses of unpurified sporozoites and by uninfected salivary glands alone. Purification of sporozoites away from mosquito salivary gland debris by density gradient centrifugation eliminated salivary gland-associated inhibition. Thus, the inhibitory effect appears to be due to exposure to uninfected mosquito salivary glands rather than sporozoites. To further assess the effect of salivary gland exposure on later sporozoite vaccinations, mice were immunized with uninfected salivary glands from a single mosquito. Compared to naive mice, salivary gland presensitization reduced subsequent liver burdens by 71%. These data show that a component(s) in mosquito salivary glands reduces liver infection, thereby limiting antigen dose and contributing to lower-magnitude T cell responses. These findings suggest that sporozoite immunogenicity studies be performed using purified sporozoites whenever feasible.
D
espite decades of research, malaria infection with Plasmodium parasites continues to cause global morbidity and mortality. The single greatest advance in the fight against malaria would be the production of a safe and effective vaccine that induces sterile immunity against Plasmodium infection. The circumsporozoite (CSP)-based RTS,S/AS01 vaccine was recently approved by the European Medicines Agency Committee for Medicinal Products for Human Use through an Article 58 regulatory procedure that allows for expanded quality, safety, and efficacy assessments outside the European Union. RTS,S achieves partial protection (1) through antibody and CD4 ϩ T cell responses (2) but does not trigger strong cytotoxic T lymphocyte (CTL) responses (3, 4) . The RTS,S vaccine does not induce sterile protection against challenge, a benchmark that is only routinely achieved through repeated immunizations with either attenuated whole sporozoites (5-7) or wild-type (WT) sporozoites with concurrent prophylactic drug coverage (8, 9) . These whole-sporozoite approaches induce protective humoral and cellular responses, and animal models suggest that protection relies on CD8 ϩ CTL (10) .
Because of the potent immunity induced by whole sporozoites, many investigators have utilized them for immunogenicity and protection studies in murine, nonhuman primate, and human immunization-challenge models. Sporozoites are transmitted to the mammalian host by blood-feeding female Anopheles mosquitoes. Sporozoites are delivered into the skin along with salivary gland components during a blood meal. Some sporozoites egress from the skin into the peripheral circulation and then infect hepatocytes, where they undergo a highly proliferative but asymptomatic expansion of asexual-stage daughter merozoites. At the conclusion of the liver stage, merozoites are released from hepatocyte-derived merosomes and go on to infect erythrocytes. The ensuing erythrocyte stage leads to cyclical destruction of erythrocytes, all clinical disease manifestations, and the eventual production of gametocytes for transmission back to the mosquito vector. Whole-sporozoite-based vaccines have the potential to inhibit primary infection of hepatocytes and to induce killing of already infected hepatocytes during the asymptomatic preerythrocytic stage, interrupting the parasite life cycle.
Since in vitro culture systems are not yet well developed for sporozoites, Plasmodium sporozoites must be reared in Anopheles insectaries. When female mosquitoes contain salivary gland-stage sporozoites, laboratory-reared mosquitoes can transmit these parasites by feeding on animal or human hosts. More commonly, sporozoite-containing salivary glands are dissected, triturated, irradiated (if applicable), and injected into the host. Both mosquito bite and injection approaches yield reliable infections provided that a sufficient number of bites or injected material are used (11) (12) (13) (14) (15) . These approaches often ignore the fact that feeding mos-quitoes also release mosquito-derived components that modulate hemostasis and immune responses and that this material is also present in dissected salivary gland preparations. There is growing evidence that both innate and adaptive immune responses are impacted by Anopheles saliva (16) and more widespread recognition that arthropod saliva in general can markedly increase or decrease pathogen infectivity depending on the vector, pathogen, and host (17) . Of interest here, Anopheles antigens are known humoral immune targets; antibody titers against mosquito salivary gland extracts are even indicative of mosquito biting intensity (18) . Constituent salivary gland proteins are increasingly well identified (19) , and some proteins, such as salivary gland protein-4 and -5, are known antibody targets (20) . Aside from humoral immunity, A. stephensi bites also activate mast cells and contribute to T cell hyperplasia in lymph nodes (21) . In a pathogenesis study, washed sporozoites were intradermally administered in the concurrent presence or absence of feeding uninfected mosquitoes (22) . When these mice progressed to blood-stage infection, those that underwent concurrent mosquito feeding demonstrated higher parasitemias, greater progression to cerebral malaria, higher levels of interleukin-4 (IL-4) and IL-10, and decreased dendritic cells (DC) and monocyte recruitment than infected mice that did not receive concurrent mosquito bites (22) . Immunosuppression may also occur when mosquito saliva is present. In a model OVA antigen system, mosquito bites induced mast cell degranulation and IL-10-mediated immunosuppression of antigen-specific T cell responses even 7 days after mosquito bite exposure (23) . Others have also postulated that skin stage-initiated immunosuppression could explain reduced efficacy of malaria vaccines in endemic settings (24) . These studies further demonstrate that mosquito component(s) alter the outcome of infection. Despite these insights, exactly how innate and adaptive immune responses to malaria parasites rise and fall following mosquito saliva exposure remains largely unknown.
Most malaria studies have tested mosquito saliva in single exposures and have not identified a strong immunomodulatory effect in murine studies. For instance, Plasmodium liver-stage infection via injected unpurified sporozoites or infected mosquito bites induces a type I interferon (IFN) response that renders mice refractory to subsequent infection within days of the previous infection. This type I IFN response is not induced by injection of uninfected unpurified salivary glands or by bites of uninfected mosquitoes (25) . Similarly, injection of unpurified sporozoites, but not injection of uninfected salivary glands, leads to expansion of activated CD8 ϩ /CD11a HI T cells (26) . However, little is known about the longer-term effects of mosquito salivary gland exposure on adaptive CD8 ϩ T cell responses that are thought to be critical for liver-stage immunity.
In our laboratory, we are interested in defining the T cell repertoire induced by whole-sporozoite immunization in order to define the components required for multiantigen subunit vaccines. CSP is a critical component for subunit vaccines, and CTL responses to CSP appear to increase in frequency with repeated immunization in the typical immunization regimen of three doses of 1 ϫ 10 4 P. yoelii radiation-attenuated sporozoites (RAS) (27) . CSP-specific responses can markedly reduce the liver burden in animal models of malaria. CSP is the sole malaria parasite component of the RTS,S vaccine, but it may be insufficient to achieve complete protection. We (27) and others have searched for non-CSP antigens that can augment the partial protection afforded by CSP-specific immunity (28) (29) (30) (31) (32) . Using sporozoite hyperimmunization, we recently proposed that responses to preerythrocytic Plasmodium CD8 antigens could be divided into two groups, a group boosted by repeated homologous sporozoite exposure (e.g., CSP-specific CD8 ϩ T cell responses) and a group that is not (27) . Building on these two classes of antigens, we have attempted to use novel whole-sporozoite vaccination strategies to increase responses to boostable antigens in an effort to reduce the number of sporozoite doses required to achieve protection. Here, we report on studies where high-dose sporozoite boosting was used to further delineate the difference between preformed CSP and the liver-stage L3 antigen. Our findings illustrate that high-dose sporozoite injection concurrently delivers mosquito component(s) that dramatically alter the parasite antigen-specific immune response and provide evidence for an improved approach for studying immunogenicity against preerythrocytic Plasmodium parasites.
MATERIALS AND METHODS
Mice. Female BALB/cj mice (4 to 6 weeks old) were obtained from Jackson Laboratories (Barr Harbor, ME), housed in an IACUC-approved animal facility, and used under an approved IACUC protocol.
Sporozoite vaccination and challenge. WT green fluorescent protein/ luciferase-expressing P. yoelii 17XNL (P. yoelii WT GFP/luc) and P. yoelii fabb/f Ϫ/Ϫ (genetically attenuated parasite [GAP]) sporozoites were obtained by salivary gland dissection from A. stephensi mosquitoes reared at the Insectary at the Center for Infectious Disease Research (CID Research, Seattle, WA). Where indicated, radiation-attenuated sporozoites (RAS) were generated from WT P. yoelii by exposure to 10,000 rads through an X-ray irradiator (Rad Source, Suwanee, GA). RAS and GAP sporozoites were administered intravenously in a volume of 150 l per mouse. Multiply immunized mice were vaccinated at 3-week intervals. Unpurified sporozoites were diluted in Schneider's insect medium and injected without further purification after dissection. Where indicated, sporozoite purification was conducted prior to irradiation using the Accudenz gradient method (33) . After layering one part salivary gland sporozoites over three parts 17% (wt/vol) Accudenz and centrifugation as reported previously (33) , the top one-third of the gradient was transferred to a fresh tube, diluted with at least four parts Schneider's medium, aliquoted into 1.6-ml tubes, and centrifuged at 17,000 ϫ g for 4 min. Pellets from these tubes were combined and the sporozoites counted using a hemocytometer. In some experiments, uninfected salivary glands (USG) were obtained from uninfected mosquitoes, diluted in Schneider's media, and used either unpurified or post-Accudenz purification. In some experiments, unpurified sporozoites were heat killed by incubation at 55°C for 30 min.
Recombinant Listeria immunization. Construction of wild-type Listeria monocytogenes expressing an H2-K d -specific epitope from P. yoelii L3 (strain LmL3) was previously reported (27) . Doubly attenuated L. monocytogenes (actA and inlB deficient) expressing an H2-K d -specific epitope, SYVPSAEQI, from P. yoelii CSP (strain LmCSP) was a kind gift of Aduro Biotech. LmL3 and LmCSP were grown to log phase, 1 ϫ 10 4 or 1 ϫ 10 5 CFU, respectively, and then diluted in phosphate-buffered saline and injected intravenously. Ex vivo IFN-␥ ELISPOT assay. For enzyme-linked immunosorbent spot (ELISPOT) assays, peptides (1 g/ml final concentration) were combined with 1 ϫ 10 6 murine splenocytes by murine gamma interferon (IFN-␥) ELISPOT assay (Affymetrix, Inc., Santa Clara, CA) and cultured for 18 h at 37°C as reported previously (27) . For ELISPOT assays from L. monocytogenes experiments, 1 ϫ 10 5 splenocytes from sensitized animals were combined with 5 ϫ 10 5 naive splenocytes per well. Liver-stage Plasmodium 18S rRNA assays. Forty-four hours postchallenge, mice were sacrificed and half of the total liver was excised and pulverized by bead beating in 5 ml NucliSENS lysis buffer (bioMérieux, Marcy-l'Étoile, France). Total nucleic acids were extracted by processing 100 l of the NucliSENS buffer-treated sample diluted 1:10 in NucliSENS lysis buffer on the EasyMag system (bioMérieux, Marcyl'Étoile, France) as described for whole blood (34) . RNA was subjected to quantitative reverse transcription-PCR (qRT-PCR) using the One-
Step AgPath RT-PCR kit (Invitrogen, Waltham, MA) using a predesigned hexachlorofluorescein-labeled mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) qRT-PCR assay (IDT Inc., Coralville, IA) multiplexed with a pan-Plasmodium assay. The pan-Plasmodium 18S rRNA reagents consisted of a CAL Fluor Orange 560-labeled pan-Plasmodium probe (5=[CAL Fluor Orange 560]-ACCGTCGTAATCTTAACC ATAAACTA[T(BHQ1)]GCCGACTAG-[spacer C3]-3=; LCG Biosearch Technologies, Navato, CA) and adjacent primers (forward, 5=-AAAGTT AAGGGAGTGAAGA-3=; reverse, 5=-AAGACTTTGATTTCTCATAAG G-3=) under conditions of 45°C for 20 min, 95°C for 15 min, and 45 cycles of 95°C for 20 s, 50°C for 30 s, and 60°C for 30 s on a CFX96/1000C real-time PCR machine (Bio-Rad, Hercules, CA). Data were normalized to mouse GAPDH and transformed to relative log 10 values to determine log 10 copy number reduction in Plasmodium 18S rRNA compared to the control group.
Luciferase-based in vivo parasite imaging. In some experiments, liver burden was measured prior to sacrifice using an in vivo bioluminescent imager (Xenogen IVIS Spectrum; Caliper Life Sciences, USA) as described previously (35) . Briefly, mice previously infected with P. yoelii WT GFP/luc were injected intraperitoneally (i.p.) with RediJect D-Luciferin (PerkinElmer) prior to undergoing isoflurane anesthesia. Bioluminescence was acquired and measured as previously reported using a 1-min acquisition time. IVIS images were quantitatively evaluated using Living Image 4.5 software (Perkin-Elmer) with regions of interest (ROIs) placed around the abdominal area overlying the liver. ROI measurements were recorded as average radiance (p/s/cm 2 /sr). B cell depletion experiments. Anti-CD20 antibody (clone 5D2 IgG2a) was provided by Genentech. BALB/cj mice were injected with 250 g of anti-CD20 1 day prior to primary immunization with USG from a single mosquito (1USG). Three weeks later, mice were injected again with anti-CD20 and administered a dose of sporozoites the following day as described in Results. B cell depletion was confirmed by evaluating peripheral blood for the presence of B220 ϩ cells in the single-cell lymphocyte gate on a FACSCanto II flow cytometer (BD, Franklin Lakes, NJ).
Statistics. ELISPOT assay comparisons were by unpaired, two-tailed Student's t tests. Comparisons of liver burden (qRT-PCR and IVIS) were by nonparametric Mann-Whitney tests.
RESULTS
In an effort to identify preerythrocytic malaria parasite vaccine candidates, we hypothesized that a larger intravenous booster dose of attenuated sporozoites can secondarily expand memory T cell populations and distinguish boostable responses (e.g., CSPspecific CD8 ϩ T cell responses) from those that do not boost during the second exposure (e.g., L3-specific CD8 ϩ T cell responses). To test this, we immunized BALB/cj mice using an intravenous prime-boost vaccination of 1 ϫ 10 4 P. yoelii RAS followed 3 weeks later by 1.5 ϫ 10 5 P. yoelii RAS. Responses were compared to those of naive mice that received 1.5 ϫ 10 4 P. yoelii RAS only. The parasites were obtained using the traditional method of salivary gland dissection without further purification. IFN-␥ ELISPOT assay performed 6 days after the final immunization showed that both CSP-and L3-specific T cell responses were of lower magnitude than those after a single exposure to 1.5 ϫ 10 5 P. yoelii RAS (Fig. 1A and B) . This effect was also observed when the P. yoelii GAP vaccine was used in lieu of P. yoelii RAS at the booster time point (see Fig. S1 in the supplemental material).
In previous work, multiple immunizations with 1 ϫ 10 4 P. yoelii RAS led to increased CSP-specific T cell responses and decreased L3-specific T cell responses, although the previously reported outcomes were measured after three immunizations (27) . Therefore, the decreasing CSP-specific T cell response frequency was surprising considering that a much larger booster dose was used here than in previous experiments. We hypothesized that an unknown component(s) in the sporozoite-containing salivary glands inhibited Plasmodium antigen-specific T cell responses. To test for inhibitory component(s), we employed a heterologous intravenously administered prime-boost approach consisting of RAS (1 ϫ 10 4 ) followed 3 weeks later by L. monocytogenes expressing the L3 H2-K d -restricted epitope (LmL3). This regimen induces extremely high-frequency secondary responses by cytotoxic L3-specific CD8 ϩ T cells (Fig. 1C ) but does not protect against sporozoite challenge (27) . However, when LmL3 was coadministered with 1.5 ϫ 10 5 RAS in RAS presensitized mice, the L3-spe- 4 unpurified P. yoelii RAS (Py10) as described for panels A and B, and 3 weeks later they were exposed to L3-producing L. monocytogenes (LmL3), LmL3 combined with 1.5 ϫ 10 5 unpurified P. yoelii RAS (LmL3ϩPy150), LmL3 combined with 1.5 ϫ 10 5 unpurified heat-killed P. yoelii RAS (LmL3ϩHKPy150), or LmL3 combined with an equivalent number of unpurified salivary glands from uninfected mosquitoes (LmL3ϩUSG). ELISPOT assay was performed with antigenic L3 peptide 6 days later as described for panel B. In all injections, parasites were obtained by salivary gland dissection without further purification. All immunizations were 150-l intravenous injections. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ns (not significant), P Ͼ 0.05 (Student's t test). Each mouse is represented by an individual circle. Error bars show 95% confidence intervals.
cific T cell response was decreased 12.5-fold (P Ͻ 0.001), suggesting that the inhibitory component(s) could even stop T cell expansion by the recombinant Listeria booster. This inhibitory effect was also observed when LmL3 was coadministered with 1.5 ϫ 10 5 heat-killed sporozoites or with USG derived from an equivalent number of mosquitoes used to obtain this many sporozoites. The finding that USG inhibited parasite-specific immune responses suggested that the inhibitory component(s) was not sporozoite derived but rather mosquito derived.
To determine if mosquito-derived inhibitory component(s) could be separated from those of sporozoites, sporozoite-containing salivary glands were subjected to density gradient purification using the Accudenz purification method. In these purifications, we achieved ϳ50% recovery of sporozoites, less than the near-perfect recovery originally reported (33) . The procedure provided highly purified sporozoites that were microscopically free of the debris present in unpurified sporozoite samples. Purified and unpurified sporozoites demonstrated equal infectivity and immunogenicity in singly exposed, previously naive BALB/cj mice (Fig. 2) , indicating that purification did not weaken the parasites or provide any adjuvant-like effects.
We next directly compared the T cell responses in mice sensitized to 1 ϫ 10 4 purified RAS followed by boosting with 1.5 ϫ 10 5 unpurified or purified RAS. CSP-specific CD8 ϩ T cell response frequencies were significantly higher in animals secondarily receiving purified sporozoites (Fig. 3A) . There was no difference in the relatively low response frequencies observed for the L3-specific responses (Fig. 3B) , consistent with our understanding of L3 expression (27) . In some experiments, the 
FIG 3 Density gradient-purified P. yoelii sporozoites more strongly expand secondary antigen-specific T cell responses than unpurified sporozoites. (A and B)
Mice were primed with 1 ϫ 10 4 unpurified P. yoelii RAS (Py10) and 3 weeks later were exposed to 1.5 ϫ 10 5 unpurified or purified P. yoelii RAS as indicated. ELISPOT assay was performed for CSP (A) and L3 (B) 6 days after the final immunization. (C) Mice were left unprimed or were primed with 1 ϫ 10 4 unpurified P. yoelii RAS (Py10) and 3 weeks later were exposed to CSP-producing L. monocytogenes (LmCSP), LmCSP combined with 1.5 ϫ 10 5 purified P. yoelii RAS (LmCSPϩPy150pure), or LmCSP combined with the gradient fraction corresponding to the sporozoite fraction from a gradient containing only uninfected mosquito salivary glands (LmCSPϩUSGpure). ELISPOT assays shown in panels A to C were performed as described in the legend to Fig. 1 . *, P Ͻ 0.05; ****, P Ͻ 0.0001 (Student's t test). ns, not significant. Each mouse is represented by an individual circle. Error bars indicate 95% confidence intervals. difference between purified and unpurified sporozoite boosting has been less marked (data not shown). Such results were obtained when sporozoites were prepared from mosquitoes with extremely high salivary gland sporozoite infectivity (i.e., high sporozoite count per mosquito). In these situations, dissected sporozoites were diluted in a larger-than-normal volume of media, presumably diluting the mosquito component(s) and minimizing their inhibitory effect. To determine if the Listeria booster model could induce high-frequency T cell responses in the presence of purified sporozoites, we performed another sporozoite-L. monocytogenes prime-boost, this time using a CSP epitope (SYVPSAEQI)-expressing attenuated LmCSP. When RAS-presensitized animals were administered LmCSP with 1.5 ϫ 10 5 purified RAS, there was no significant difference compared to boosting by LmCSP alone (Fig. 3C) . Similarly, when using a gradient fraction corresponding to the sporozoite interface from a gradient only containing USG, there was also no inhibition of the LmCSP boosting effect (Fig. 3C) . These data suggest that the mosquito-derived inhibitor(s) in USG was removed by gradient purification.
The mechanistic basis of inhibition by USG exposure is unknown. Because the effect was most marked in the L. monocytogenes model at the secondary time point, it is possible that mosquito-specific immune responses resulted in "off-target" immune responses that overwhelmed antigen processing and/or presentation of codelivered parasite antigens. Mosquito-specific immune responses do have the potential to reduce the liver burden in a mosquito bite model of infection (36) . While such responses do not achieve sterile protection (37) , three rounds of presensitization via bites of 15 to 20 A. stephensi mosquitoes at each exposure reduced the liver burden following infectious mosquito bite challenge by 9-fold compared to that of mosquito bite-naive mice (36) . To determine if such reductions also occurred in the intravenous exposure model, we presensitized some mice with 1USG (equivalent to the salivary gland dose when 1 ϫ 10 4 unpurified RAS are administered) and later challenged naive and presensitized mice with 8 ϫ 10 4 unpurified WT P. yoelii sporozoites. Forty-four hours later, the liver-stage parasite burden was reduced by 71% compared to that of naive mice as measured by liver qRT-PCR (P Ͻ 0.0001) (Fig. 4A) . Bioluminescent imaging of the P. yoelii WT GFP/luc preerythrocytic parasites at 44 h postinfection corroborated these measurements (Fig. 4B) . In a subsequent experiment, naive mice or mice presensitized with 1USG derived from one mosquito were challenged with 8 ϫ 10 4 unpurified or purified P. yoelii WT GFP/luc sporozoites. Liver burden again was monitored by IVIS bioluminescent imaging at 44 h (Fig. 5) . Whereas presensitized mice again showed a reduction in liver burden comparable to that shown in Fig. 4 , 1USG-sensitized mice challenged with purified sporozoites showed no such reduction.
To study the role of anti-mosquito antibodies in the observed reduction in liver burden, BALB/cj mice were immunized with 1USG in the presence or absence of anti-CD20 B cell-depleting antibodies (kind gift of Genentech). Three weeks later, B celldepleted mice were treated with anti-CD20 again and all mice were challenged with 8 ϫ 10 4 P. yoelii WT GFP/luc sporozoites 1 day later. Anti-CD20 staining of peripheral blood confirmed a Ͼ30-fold reduction in B cells in the antibody-treated mice (see Fig. S2A in the supplemental material) . At 44 h postchallenge, liver burden was assessed by IVIS bioimaging. B cell-depleted mice demonstrated a mean liver burden that was 1.7-fold higher than that of B cell-competent mice, although this difference did not reach statistical significance (see Fig. S2B ). In summary, intravenous exposure to even a small quantity of mosquito salivary glands contributes to a quantitative reduction in parasite liver burden following secondary sporozoite exposure and accounts in part for the decreased CD8 ϩ T cell responses observed following boosting with large doses of unpurified sporozoites. Although reduced liver burden is considered beneficial following wild-type sporozoite challenge, reductions in liver burden may be counterproductive during sporozoite vaccination. Purification of sporozoites appears to circumvent these reductions and increase immunogenicity. 
DISCUSSION
Many laboratories use Plasmodium sporozoites in preclinical and clinical immunization studies to study mechanisms of antimalarial immunity, find protective subunit antigens, and identify effective whole-organism vaccine dosing regimens. In most preclinical studies, sporozoites are administered via either mosquito bites or injections of unpurified sporozoites. While the effects of mosquito saliva on sporozoite immunization are not well understood, it is clear that mosquito component(s) affect vaccine potency. For instance, sterile protection against homologous challenge in BALB/c mice is usually achieved only after a cumulative intravenous dose of Ն5 ϫ 10 4 unpurified P. yoelii RAS administered across 2 to 3 doses (reviewed in reference 38). In contrast, immunization with a 25-fold smaller dose of purified, freshly dissected P. yoelii RAS (3 doses of 750) resulted in CD8 ϩ -dependent sterile protection in BALB/c mice (39) . Our findings now provide immunological insight that explains the markedly improved protection reported for purified P. yoelii RAS immunizations compared to that of unpurified sporozoites.
Our data show that the use of unpurified sporozoites for antigen discovery could lead to the false conclusion that antigen-specific responses cannot be boosted by sporozoites. The inhibitory effect was mediated by USG alone and removed by density gradient centrifugation. When purified sporozoites were utilized, CSPspecific CD8 ϩ T cell responses were increased relative to a similar secondary exposure to unpurified sporozoites. Although antibodies to mosquito salivary component(s) may play a role in these observed outcomes, the elimination of B cells using depleting anti-CD20 antibodies did not illustrate this effect. A recent intravital imaging study on the mechanism of anti-CD20-mediated B cell depletion (40) suggests that the outcome of our experiment was unexpectedly influenced by the antibody-dependent mechanism of B cell depletion itself. This study showed that anti-CD20 treatment leads to antibody-dependent phagocytosis of B cells by Kupffer cells in the liver (40) . Kupffer cells usually act as silent portals of liver entry for sporozoites (41, 42) but can reduce liver infection when nonspecifically activated (43) . It is possible that systemic depletion of B cells by anti-CD20 treatment could activate Kupffer cells and nonspecifically reduce the parasite liver burden. Kupffer cell activation could have counteracted the increase in liver burden that we hypothesized would occur with loss of anti-mosquito antibodies.
Preexposure to parasite and/or mosquito components can decrease the liver burden and in turn affect immune responses. With respect to mosquito components, Donovan and colleagues showed that three rounds of 15 to 20 uninfected mosquito bites led to an IFN-␥-dependent 9-fold reduction in liver burden postchallenge and modestly delayed the growth of the subsequent erythrocyte-stage parasites 5 to 7 days postchallenge compared to that of mosquito-naive mice (36) . We found that preexposure to 1USG could reduce liver burden following challenge with unpurified sporozoites. The 1USG dose administered 3 weeks prior to challenge conferred a 71% decrease in parasite liver burden compared to that of mice naive to mosquito USG. This reduction may explain the reduced immunogenicity observed when unpurified sporozoites were used repeatedly. In contrast, infection by purified sporozoites was not reduced by mosquito USG presensitization. Sterile protection against sporozoite challenge requires greater reductions in liver burden (Ͼ99%), and mosquito salivary gland presensitization does not achieve this level of protection. For instance, preexposure to Anopheles saliva (equivalent to USG from 0.5 mosquito per dose) did not induce sterile protection and had no effect on the development of patent parasitemia (37) . While mosquito preexposure may not prevent the onset of patent parasitemia following challenge, such exposures have a major effect on the immunogenicity of immunizing doses of live sporozoites.
The number of immunizing parasites that ultimately develop in the liver is a function of the total sporozoite dose, degree of attenuation, route of administration, and prior host immunity against parasite and mosquito components. Controlled human malaria infection studies show clear dose dependence both for the injected Plasmodium falciparum NF54 irradiated, cryopreserved sporozoite vaccine (PfSPZ) (44) and for bites from P. falciparum-
FIG 5
Purification of sporozoites circumvents the protection provided by preexposure to intravenously administered mosquito salivary glands. BALB/cj mice were injected with nothing or with 1USG as described in the legend to Fig. 4 . Three weeks later, all mice were injected with 8 ϫ 10 4 unpurified or purified P. yoelii WT GFP/luc sporozoites, and 44 h later liver-stage burden was assessed by bioluminescent imaging (A and B) as described for Fig. 4 . Groups include naive mice challenged with unpurified sporozoites (None ¡ UnpurePy80), mice challenged with purified sporozoites (None ¡ PurePy80), or mice preexposed to 1USG and then challenged with unpurified sporozoites (1USG ¡ UnpurePy80) or with purified sporozoites (1USG ¡ PurePy80). **, P Ͻ 0.01 (Mann-Whitney test). Each mouse is represented by an individual circle. Error bars indicate 95% confidence intervals.
infected irradiated mosquitoes (45) . Irradiated sporozoites are highly attenuated, and for mosquito bite-delivered vaccinations, large numbers of infected mosquitoes bites are routinely used to deliver the high doses needed to achieve protection (multiple exposures to ϳ100 to 200 bites per subject per vaccination dose). A review of mosquito bite-delivered irradiated P. falciparum sporozoite immunization studies calculated that 25% of subjects who sustained Ͻ950 infected mosquito bites were protected from homologous challenge, whereas 93% of those receiving Ͼ1,000 immunizing bites were protected (45) . A high number of immunizing bites is due partly to the fact that each individual mosquito only transmits a relatively small number of sporozoites (46), but it is also possible that the cumulative effect of repeated exposures to mosquito components reduces the efficacy of each subsequent dose of mosquito bite-delivered vaccine. Sporozoite purification may confer a dose-sparing effect on the vaccination regimen, as previously observed in murine studies (39) . The number of bites required to achieve protection was also dramatically reduced when nonirradiated mosquitoes carrying WT sporozoites were used under concurrent chloroquine coverage in human studies (9) . The improved outcome was likely due to the greater fitness of wild-type sporozoites and possibly also to reduced cumulative exposure to mosquito components. Since preexposure to mosquito salivary gland components alone reduces the liver burden (perceived beneficial outcome postchallenge) and immunogenicity (perceived negative outcome), previous vaccine studies that relied on unpurified sporozoite injections or repeated mosquito bites may have overestimated parasite-specific protection and underestimated sporozoite vaccine immunogenicity.
Based on these findings, we advocate that immunogenicity studies be conducted using purified sporozoites. PfSPZ (Sanaria Inc., Rockville, MD), used in human clinical studies (39, 44, 47, 48) , is reared in aseptic mosquitoes, and the sporozoites are filtered to remove mosquito salivary gland material and ensure product sterility (e.g., no microbial contamination) but not expressly to improve immunogenicity. During manufacturing, sporozoites are also concentrated and cryopreserved (49) . The findings here suggest that this manufacturing process improves PfSPZ immunogenicity. Many phase I and II vaccine trials are under way using whole sporozoites, including the Sanaria PfSPZ product as well as other mosquito bite-delivered sporozoites. Because vialed sporozoites can be concentrated, even high doses can be delivered in the small volumes used for syringe-based injection. Sanaria's in-house data indicate that the purification process provides for a near absence of mosquito-derived protein in the PfSPZ material based on mosquito-specific enzyme-linked immunosorbent assay (S. Hoffman, personal communication), although it remains unknown whether these sporozoites contain any other mosquito-derived carbohydrate and/or lipid moieties. For instance, salivary gland sporozoites were recently shown to possess a likely mosquito-derived ␣-gal glycan that was able to serve as a protective IgM antibody target in the reported mouse studies (50) . Dose escalation of PfSPZ has generally shown increased efficacy (44) , but if further escalation were to reveal a paradoxical reduction in efficacy at extremely high doses, anti-mosquito responses could be involved. For mosquito bite-delivered vaccinations, sporozoites are not separated from mosquito saliva. Recently, the small-scale in vitro culture of sporozoites was also reported (51), but it remains to be seen whether in vitro-produced sporozoites carry non-Plasmodium moieties that can affect anti-sporozoite immunogenicity. Our studies here were conducted using injected salivary gland material, and it remains unknown whether the same effect would be observed using natural mosquito bites. Nonetheless, given our findings and the previous report that uninfected mosquito bites reduce the liver burden in challenged mice (36), we predict that repeated exposures to mosquito saliva will decrease immunogenicity and reduce the efficacy of mosquito bite-delivered sporozoite vaccines; this remains to be formally tested in humans.
There are no previous reports detailing the outcome of parasite-specific T cell responses in the presence and absence of mosquito salivary glands. Our data now show that the presence of a mosquito component(s) in preclinical vaccines could alter conclusions made about the recall of immune responses. Here, we observed no increase in CSP-specific T cell responses following high-dose boosting with unpurified sporozoites. This finding is in agreement with data from previous studies, but all such studies were also conducted with unpurified sporozoites. In another report, multiple unpurified homologous sporozoite immunizations (3 ϫ 10 4 to 4 ϫ 10 4 /dose) at 48-h intervals led to no significant increase in CSP-specific CD8 ϩ T cell expansion (52) . At the 3 ϫ 10 4 to 4 ϫ 10 4 dose, a mosquito-derived component(s) may have negatively affected T cell recall. The previous report termed this process "self-regulation" and explained that self-regulation was due to elimination of antigen-presenting dendritic cells by cognate antigen-specific CD8 ϩ T cells (53) , which ultimately prevented further expansion of CD8 ϩ T cells specific for that antigen. In unpurified sporozoite preparations, the mosquito material is quantitatively much more abundant than the sporozoite mass, and our findings lead us to reinterpret previous data. When unpurified sporozoites are injected, antigen-presenting cells (APCs) process and present both mosquito-and sporozoite-derived antigens. It is tempting to postulate that APCs could be overwhelmed with mosquito-derived peptides, leading to mosquito-specific responses that self-regulate antigen-presenting DCs even as these APCs simultaneously present smaller quantities of parasite-derived antigens. Mosquito-derived antigens are known to induce antibody responses (54) (55) (56) (57) , and both saliva and sporozoites remain in the skin for up to 18 h postbite (58) .
Even with unpurified sporozoites, we and others (59) find that endogenous CSP-specific CD8 ϩ T cells increase in frequency after repeated lower-dose sporozoite immunizations when longer intervals between exposures are used. When we immunized mice using purified sporozoites with a large booster dose, CSP-specific T cells expanded in numbers. This is consistent with the work of others that showed that the memory pool of CD8 ϩ T cells increases with repeated immunizations (26) . Since CSP-but not L3-specific responses increase using this large purified sporozoite booster, the finding is consistent with our prediction that the increasing memory pool in sporozoite hyperimmunized animals consists mostly of cells targeting preformed or early-liver-stage antigens like CSP. Thus, purified sporozoites may prove more useful than their unpurified counterparts for antigen discovery without the potentially misleading effects from mosquito salivary glands. In addition, the use of purified sporozoites is likely to reduce competition between mosquito-and parasite-derived proteins at the level of antigen processing and presentation. We have determined that purified sporozoites should be used for immunogenicity studies whenever feasible.
